5-amino-4-anilinopyrimidine | 41259-68-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-amino-4-anilinopyrimidine
• 英文别名: N⁴-phenylpyrimidine-4,5-diamine；5-Amino-4-anilino-pyrimidin；4-N-phenylpyrimidine-4,5-diamine
• CAS: 41259-68-1
• 化学式: C₁₀H₁₀N₄
• 分子量: 186.216
• InChiKey: JBOSDOMAVZWBQA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-amino-4-anilinopyrimidine 以64%的产率得到
  参考文献：
  名称：

  HAYASHI EISAKU; SHIMADA NORIAKI; MATSUOKA YOSHIYUKI; MIWA YOSHIO, YAKUGAKU DZASSI, YAKUGAKU ZASSNI, J. PHARM. SOS. JAR., 1979, 99, NO 2, 20+

  摘要：

  DOI：
• 作为产物：
  描述：

  6-氯-N4-苯基-4,5-嘧啶二胺 以60%的产率得到
  参考文献：
  名称：

  HAYASHI EISAKU; SHIMADA NRIAKI; MATSUOKA YOSHIYUKI, YAKUGAKU DZASSI, YAKUGAKU ZASSNI, J. PHARM. SOS. JAR., 1979, 99, NO 2, 11+

  摘要：

  DOI：

文献信息

• Synthesis And Characterization Of Novel Pyrimidine-4,5-Diamine As Anticancer Agent
  作者：Maturi Someswara Rao、Tadiboina Bhaskara Rao、Cherukumalli Purna Koteswara Rao、Nagaraj Maddur

  DOI：10.26452/ijrps.v11i3.2649

  日期：——

  Unlike latent cells, cancer cells supply deoxyribonucleoside triphosphates to cells continuously and thereby, prop up the uncontrolled cancer growth. Pyrimidine has been concerned in the separation of leukemic cells, known as adenine bioisosteres, as well as its biological activities, especially its anticancer properties. In this context, a novel series of N5-(3-substituted benzylidene)-N4-phenyl pyrimidine-4,5-diamine [5A-5F] / N5-(2-substituted benzylidene)-N2,N2-dimethyl-N4-phenyl pyrimidine-2,4,5-triamine [5a-5f] were synthesized by using the starting ingredient formimidamide/4-(dimethylamino) benzimidamide and sodium ethoxide. The synthesized compounds were characterized by IR, 1H NMR, and Mass spectral analyses and screened for their biological studies. In the present study, pyrimidine derivatives and their insilico modeling were done by using c-Src kinase and p38 MAP kinase complex followed by the evaluation of their anticancer activity. The screening of synthesized scaffolds possessed significant activity against HeLa cell lines and showed similar activity compared to standard Cisplatin. Among all the synthesized compounds, N5-(4-hydroxybenzylidene)-N4-phenyl pyrimidine-4,5-diamine 5A, N5-benzylidene-N4-phenylpyrimidine-4,5-diamine 5C, N5-benzylidene-N2, N2-dimethyl-N4-phenyl pyrimidine-2,4,5-triamine 5c, and N5-(4-methoxy benzylidene)-N4-phenyl pyrimidine-4,5-diamine 5E showed the highest significant anticancer activity. Based on the study, it was observed that substituents such as 4-hydroxy, 4-fluoro, 4-nitro, 4-methoxy, and 4-methyl are important to produce a biological effect. Moreover, among these substituents, N5-(4-hydroxybenzylidene)-N4-phenyl pyrimidine-4,5-diamine exhibited the highest anticancer activity followed by unsubstituted derivative N5-benzylidene-N4-phenylpyrimidine-4,5-diamine, which delivered significant anticancer activity.

  与潜在细胞不同，癌细胞持续向细胞供应脱氧核苷三磷酸，从而支持不受控制的癌症生长。嘧啶已被认为在分离白血病细胞（称为腺嘌呤生物同源体）以及其生物活性，特别是其抗癌特性方面起作用。在这种情况下，通过使用起始成分甲酰胺基/4-(二甲氨基)苯并咪唑和乙醇钠，合成了一系列新型N5-(3-取代苄基亚甲基)-N4-苯基嘧啶-4,5-二胺[5A-5F] / N5-(2-取代苄基亚甲基)-N2,N2-二甲基-N4-苯基嘧啶-2,4,5-三胺[5a-5f]。合成化合物通过红外光谱、1H核磁共振和质谱分析进行表征，并进行了生物研究筛选。在本研究中，通过使用c-Src激酶和p38 MAP激酶复合物进行嘧啶衍生物及其分子模拟，然后评估其抗癌活性。合成支架的筛选对HeLa细胞系表现出显着活性，并显示出与标准顺铂相似的活性。在所有合成化合物中，N5-(4-羟基苄亚甲基)-N4-苯基嘧啶-4,5-二胺 5A、N5-苄亚甲基-N4-苯基嘧啶-4,5-二胺 5C、N5-苄亚甲基-N2,N2-二甲基-N4-苯基嘧啶-2,4,5-三胺 5c和N5-(4-甲氧基苄亚甲基)-N4-苯基嘧啶-4,5-二胺 5E显示出最显著的抗癌活性。根据研究，观察到4-羟基、4-氟基、4-硝基、4-甲氧基和4-甲基等取代基对产生生物效应很重要。此外，在这些取代基中，N5-(4-羟基苄亚甲基)-N4-苯基嘧啶-4,5-二胺表现出最高的抗癌活性，其次是未取代的衍生物N5-苄亚甲基-N4-苯基嘧啶-4,5-二胺，其具有显著的抗癌活性。
• HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME
  申请人：Chiosis Gabriela

  公开号：US20120252818A1

  公开（公告）日：2012-10-04

  The present subject matter relates to a compound represented by the general formula (I) or (I′) or a pharmacologically acceptable salt thereof; pharmaceutical compositions containing at least one of these compounds; methods of making at least one of these compounds; methods of using at least one of these compounds for treating and/or preventing various cancers and/or proliferation disorders; methods of using at least one of these compounds for monitoring the effectiveness of an anticancer therapy against various cancers. In one embodiment, the subject matter relates to compounds that bind with a level of specificity to heat shock protein 70 (Hsp70). In another embodiment, the subject matter relates to compounds that bind with a level of specificity to inhibit both heat shock protein 70 (Hsp70) and heat shock cognate protein 70 (Hsc70).

  本主题涉及一种由通式(I)或(I′)表示的化合物或其药学上可接受的盐；包含至少一种这些化合物的制药组合物；制备至少一种这些化合物的方法；使用至少一种这些化合物治疗和/或预防各种癌症和/或增殖障碍的方法；使用至少一种这些化合物监测抗癌治疗对各种癌症的有效性的方法。在一种实施方式中，本主题涉及与热休克蛋白70（Hsp70）具有特异性结合的化合物。在另一种实施方式中，本主题涉及与具有特异性抑制热休克蛋白70（Hsp70）和热休克同源蛋白70（Hsc70）的化合物的结合。
• Heat shock protein binding compounds, compositions, and methods for making and using same
  申请人：Memorial Sloan-Kettering Cancer Center

  公开号：US10052325B2

  公开（公告）日：2018-08-21

  The present subject matter relates to a compound represented by the general formula (I) or (I′) or a pharmacologically acceptable salt thereof; pharmaceutical compositions containing at least one of these compounds; methods of making at least one of these compounds; methods of using at least one of these compounds for treating and/or preventing various cancers and/or proliferation disorders; methods of using at least one of these compounds for monitoring the effectiveness of an anticancer therapy against various cancers. In one embodiment, the subject matter relates to compounds that bind with a level of specificity to heat shock protein 70 (Hsp70). In another embodiment, the subject matter relates to compounds that bind with a level of specificity to inhibit both heat shock protein 70 (Hsp70) and heat shock cognate protein 70 (Hsc70).

  本主题涉及通式(I)或(I′)代表的化合物或其药理学上可接受的盐；含有至少一种这些化合物的药物组合物；制造至少一种这些化合物的方法；使用至少一种这些化合物治疗和/或预防各种癌症和/或增殖障碍的方法；使用至少一种这些化合物监测抗癌疗法对各种癌症的疗效的方法。在一个实施方案中，该主题涉及与热休克蛋白 70（Hsp70）具有一定特异性结合的化合物。在另一个实施方案中，本发明涉及的化合物具有一定程度的特异性，可同时抑制热休克蛋白70（Hsp70）和热休克同源蛋白70（Hsc70）。
• Higashino, Takeo; Sato, Susumu; Miyashita, Akira, Chemical and pharmaceutical bulletin, 1987, vol. 35, # 12, p. 4803 - 4812
  作者：Higashino, Takeo、Sato, Susumu、Miyashita, Akira、Katori, Tatsuhiko

  DOI：——

  日期：——
• HIGASHINO, TAKEO;SATO, SUSUMU;MIYASHITA, AKIRA;KATORI, TATSUHIKO, CHEM. AND PHARM. BULL., 35,(1987) N 12, 4803-4812
  作者：HIGASHINO, TAKEO、SATO, SUSUMU、MIYASHITA, AKIRA、KATORI, TATSUHIKO

  DOI：——

  日期：——